Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.06 | -0.03 | 0.03 |
| FCF Yield | 6.44% | -4.36% | 2.31% | -8.17% |
| EV / EBITDA | 21.11 | 18.04 | 14.35 | -3.93 |
| Quality | ||||
| ROIC | -2.23% | -1.00% | -9.87% | -14.54% |
| Gross Margin | 59.69% | 61.42% | 56.36% | 39.55% |
| Cash Conversion Ratio | -0.45 | 0.51 | -0.13 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.44% | -9.30% | -16.49% | -16.74% |
| Free Cash Flow Growth | 226.09% | -330.21% | 120.89% | -437.89% |
| Safety | ||||
| Net Debt / EBITDA | -1.06 | -0.56 | -1.69 | 0.66 |
| Interest Coverage | -0.49 | 0.00 | -20.85 | -57.33 |
| Efficiency | ||||
| Inventory Turnover | 1.56 | 1.35 | 1.17 | 1.24 |
| Cash Conversion Cycle | 99.21 | 111.32 | 142.05 | 120.93 |